Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

'Immunotherapies like pembrolizumab have proved to be effective as second-line treatments for advanced disease. Now,... we are starting to see significant efficacy for immunotherapies as first-line treatment for advanced cancers with specific genetic signatures...,' said ASCO President Howard Burris

Like Comment

Front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival vs chemotherapy in patients with a type of advanced colorectal cancer that has a high number of mutations, which previous research suggests may have a poor prognosis for some patients. This is the first time pembrolizumab has been shown to benefit these patients when used as a front-line therapy.

The findings come from an interim analysis of the phase III KEYNOTE-177 trial that was presented during the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Study at a Glance 

Focus  

 Pembrolizumab as a front-line therapy in patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal carcinoma 

Population  

 307 patients with metastatic disease 

Findings  

 Pembrolizumab improved progression-free survival by 8.3 months 

Significance  

 Supports pembrolizumab as the new standard of care as first-line therapy 

To view full article and watch the video summary,
register to OnMedica and then click
'View full content'.

 

OnMedica

Editorial team, Wilmington Healthcare

OnMedica is an independent, easy to access on-the-go website for doctors. It provides GPs and specialists with easy to digest and up-to-date, relevant educational content whilst enabling the freedom to share and collaborate in a safe-space to further personal development.
2989 Contributions
43 Followers
1 Following

No comments yet.